137 related articles for article (PubMed ID: 24810181)
1. Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Xiong H; Chiu YL; Ricker JL; LoRusso P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):55-61. PubMed ID: 24810181
[TBL] [Abstract][Full Text] [Related]
2. Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
Chiu YL; Carlson DM; Pradhan RS; Ricker JL
Clin Ther; 2013 Nov; 35(11):1770-7. PubMed ID: 24094464
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
[TBL] [Abstract][Full Text] [Related]
4. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.
Salem AH; Koenig D; Carlson D
Clin Pharmacokinet; 2014 Apr; 53(4):347-59. PubMed ID: 24307488
[TBL] [Abstract][Full Text] [Related]
5. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Asahina H; Tamura Y; Nokihara H; Yamamoto N; Seki Y; Shibata T; Goto Y; Tanioka M; Yamada Y; Coates A; Chiu YL; Li X; Pradhan R; Ansell PJ; McKeegan EM; McKee MD; Carlson DM; Tamura T
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1477-86. PubMed ID: 22382879
[TBL] [Abstract][Full Text] [Related]
6. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Toh HC; Chen PJ; Carr BI; Knox JJ; Gill S; Ansell P; McKeegan EM; Dowell B; Pedersen M; Qin Q; Qian J; Scappaticci FA; Ricker JL; Carlson DM; Yong WP
Cancer; 2013 Jan; 119(2):380-7. PubMed ID: 22833179
[TBL] [Abstract][Full Text] [Related]
8. Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.
Chiu YL; Lorusso P; Hosmane B; Ricker JL; Awni W; Carlson DM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):213-7. PubMed ID: 24241212
[TBL] [Abstract][Full Text] [Related]
9. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Wong CI; Koh TS; Soo R; Hartono S; Thng CH; McKeegan E; Yong WP; Chen CS; Lee SC; Wong J; Lim R; Sukri N; Lim SE; Ong AB; Steinberg J; Gupta N; Pradhan R; Humerickhouse R; Goh BC
J Clin Oncol; 2009 Oct; 27(28):4718-26. PubMed ID: 19720910
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
Tan EH; Goss GD; Salgia R; Besse B; Gandara DR; Hanna NH; Yang JC; Thertulien R; Wertheim M; Mazieres J; Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci FA; Ricker JL; Carlson DM; Soo RA
J Thorac Oncol; 2011 Aug; 6(8):1418-25. PubMed ID: 21597387
[TBL] [Abstract][Full Text] [Related]
11. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
[TBL] [Abstract][Full Text] [Related]
13. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
[TBL] [Abstract][Full Text] [Related]
14. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
[TBL] [Abstract][Full Text] [Related]
15. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
[TBL] [Abstract][Full Text] [Related]
16. Linifanib: current status and future potential in cancer therapy.
Aversa C; Leone F; Zucchini G; Serini G; Geuna E; Milani A; Valdembri D; Martinello R; Montemurro F
Expert Rev Anticancer Ther; 2015 Jun; 15(6):677-87. PubMed ID: 25936222
[TBL] [Abstract][Full Text] [Related]
17. Linifanib.
Drugs R D; 2010; 10(2):111-22. PubMed ID: 20698720
[TBL] [Abstract][Full Text] [Related]
18. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Tannir NM; Wong YN; Kollmannsberger CK; Ernstoff MS; Perry DJ; Appleman LJ; Posadas EM; Cho D; Choueiri TK; Coates A; Gupta N; Pradhan R; Qian J; Chen J; Scappaticci FA; Ricker JL; Carlson DM; Michaelson MD
Eur J Cancer; 2011 Dec; 47(18):2706-14. PubMed ID: 22078932
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G; Bentley D; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Brink A; Djebli N; Mercier F; Buchheit V; Phipps A
Invest New Drugs; 2021 Jun; 39(3):803-811. PubMed ID: 33462752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
